Table 2.
Comparison of efficacy in patients after treatment
| Efficacy | Early-stage endometrial carcinoma | ||||
|
| |||||
| Complete remission (CR) | Partial remission (PR) | Stable disease (SD) | Progressive disease (PD) | Total effective rate | |
|
| |||||
| The control group (n=25) | 15 (60.0) | 3 (12.0) | 5 (20.0) | 2 (8.0) | 18 (72.0) |
| The combination group (n=31) | 27 (87.1) | 2 (6.4) | 2 (6.4) | 0 | 29 (93.5) |
| χ2/t | 4.7641 | ||||
| P-value | 0.0291 | ||||
|
| |||||
| Efficacy | Atypical endometrial hyperplasia | ||||
|
| |||||
| Complete remission (CR) | Partial remission (PR) | Stable disease (SD) | Progressive disease (PD) | Total effective rate | |
|
| |||||
| The control group (n=20) | 11 (55.0) | 3 (15.0) | 6 (20.0) | 1 (5.0) | 14 (70.0) |
| The combination group (n=27) | 23 (85.2) | 2 (7.4) | 2 (7.4) | 0 | 25 (92.6) |
| χ2/t | 4.1521 | ||||
| P-value | 0.0416 | ||||